Background and objective: Current guidelines for the diagnosis of idiopathic pulmonary fibrosis (IPF) provide specific criteria for diagnosis in the setting of multidisciplinary discussion (MDD). We evaluate the utility and reproducibility of these diagnostic guidelines, using clinical data from the Australian IPF Registry. Methods: All patients enrolled in the registry undergo a diagnostic review whereby international IPF guidelines are applied via a registry MDD. We investigated the clinical applicability of these guidelines with regard to: (i) adherence to guidelines, (ii) Natural history of IPF diagnostic categories and (iii) Concordance for diagnostic features. Results: A total of 417 participants (69% male, 70.6 AE 8.0 years) with a clinical diagnosis of IPF underwent MDD. The 23% of participants who did not
ABSTRACT
Background and objective: Current guidelines for the diagnosis of idiopathic pulmonary fibrosis (IPF) provide specific criteria for diagnosis in the setting of multidisciplinary discussion (MDD). We evaluate the utility and reproducibility of these diagnostic guidelines, using clinical data from the Australian IPF Registry. Methods: All patients enrolled in the registry undergo a diagnostic review whereby international IPF guidelines are applied via a registry MDD. We investigated the clinical applicability of these guidelines with regard to: (i) adherence to guidelines, (ii) Natural history of IPF diagnostic categories and (iii) Concordance for diagnostic features. Results: A total of 417 participants (69% male, 70.6 AE 8.0 years) with a clinical diagnosis of IPF underwent MDD. The 23% of participants who did not meet IPF diagnostic criteria displayed identical disease behaviour to those with confirmed IPF. Honeycombing on radiology was associated with a worse prognosis and this translated into poorer prognosis in the 'definite' IPF group. While there was moderate agreement for IPF diagnostic categories, agreement for specific radiological features, other than honeycombing, was poor. Conclusion: In clinical practice, physicians do not always follow IPF diagnostic guidelines. We demonstrate a cohort of IPF patients who do not meet IPF diagnostic guideline criteria, based largely on their radiology and lack of lung biopsy, but who have outcomes identical to those with IPF.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF), the most prevalent of the idiopathic interstitial pneumonias (IIP), is a relentlessly progressive disease with a median survival of only 2-5 years. [1] [2] [3] Two landmark studies in 2014 4, 5 showed, for the first time, that anti-fibrotic therapies reduce disease progression. These findings have prompted a renewed and global focus on ensuring an accurate diagnosis of IPF. 6, 7 In 2011, the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Latin American Thoracic Association (ATS/ERS/JRS/ ALAT), developed evidence-based guidelines for the diagnosis of IPF. 1 Central to these guidelines is a multidisciplinary evaluation whereby clinicians, radiologists and histopathologists reach a consensus diagnosis. 8, 9 The multidisciplinary diagnosis of IPF relies heavily on the presence of a definite usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT). However, the agreement of experienced radiologists using the ATS/ERS/JRS/ALAT criteria is only moderate. 10 In cases where definite UIP is not present radiologically, the guidelines call for a surgical lung biopsy for confirmation of diagnosis.
A rigorous diagnostic approach is appropriate for selecting homogenous, well-characterized cohorts of IPF patients to enhance the uniform recruitment for clinical trials. However, it is increasingly evident that in real-world clinical practice, not all IPF patients fulfil these criteria and physicians rely on other clinically relevant criteria not reflected in the guidelines. 11, 12 In this study, we evaluate the clinical application of the ATS/ERS/JRS/ALAT guidelines in Australia, using our national IPF registry cohort.
The Australian IPF Registry (AIPFR) recruits patients referred from across Australia with a diagnosis of IPF made by their referring respiratory physician. This diagnosis is then re-evaluated at a centralized multidisciplinary diagnostic (multidisciplinary discussion, MDD) review using the 2011 ATS/ERS/JRS/ALAT guidelines. 13 As previously highlighted, this is a process unique to the AIPFR. In evaluating the clinical application of the IPF diagnostic guidelines, we explored the adherence by Australian respiratory physicians to the guideline diagnostic criteria. Second, we investigated prognostic implications of guideline-defined IPF diagnostic categories assigned by our registry MDD panel. Finally, we evaluated the reproducibility of the guidelines by assessing the concordance of the diagnostic categories and specific UIP features between our multidisciplinary panel members.
METHODS

Study population
The AIPFR is a nationwide collaboration initiated in 2012 and administered by the Lung Foundation of Australia, collating data on incident and prevalent cases of IPF.
The registry has ethics approval to operate in every state and territory of Australia. This study has ethical approval from the Sydney Local Health District (protocol no. X14-0264). State-based coordinators consent participants and collect baseline and longitudinal information from patients and their referring physicians. Investigations collected are those performed as part of the patient's routine management only, thereby creating a real-world longitudinal cohort. Details regarding the structure and data collected in the registry have been published previously. 14 
Registry multidisciplinary diagnosis
Participants in the AIPFR undergo a multidisciplinary central diagnostic review or 'registry MDD' (Fig. S1 , Supplementary Information) at which the current ATS/ERS/JRS/ALAT criteria are applied. 1 The most recent HRCT scan is reviewed by one of the two parallel registry radiology review panels. Each radiology panel consists of three experienced pulmonary radiologists who independently review each participant's HRCT. In a similar manner, the histopathology of all participants who have undergone a surgical lung biopsy is reviewed at three independent specialist centres by expert histopathologists. The pattern is reported according to the consensus guidelines (Table S1 , Supplementary Information). A consensus result for each panel is then achieved on the basis of the individual reports, or if no consensus is reached, cases are reviewed at a meeting with all panel members.
The information described above is synthesized with clinical information by a panel of three respiratory physicians who then designate a registry MDD diagnosis: 'definite', 'probable', 'possible' and 'inconsistent' with IPF in accordance with the guidelines. A consensus registry MDD diagnosis is achieved when two or more respiratory physicians agree on the classification. In the cases where there is no majority, diagnosis is established after discussion between all clinical panel members. Importantly, an IPF category is assigned for cases that are not definite IPF based on HRCT and clinical findings, even in cases where a lung biopsy is not performed.
Statistical analysis
Baseline comparisons between diagnostic IPF categories were performed using chi-squared, Student's t-test, analysis of variance (ANOVA) or Kruskal-Wallis tests as appropriate. Linear mixed models for forced vital capacity (FVC) % predicted were fitted with random intercepts and slopes. We tested differences between diagnosis categories using an interaction term between diagnosis category and time since registry consent. The model included age, sex, smoking status and IPF diagnosis category.
Survival curves were estimated using the KaplanMeier method. Cox proportional models were used to assess overall survival, with patients who received lung transplantation censored at the date of transplant. In all multivariable models, adjustments for age, gender, smoking status and baseline FVC% predicted were made. In cases where data were incomplete, only cases with complete data sets were used for analysis.
The concordance of inter-observer UIP categories and key radiological and histopathological features was assessed using linear weighted kappa analysis. 15 In the case of radiology, features were reported as present or absent. In histopathology, features were either absent, present or prominent.
All results with a P-value of <0.05 were reported as significant. All statistical analysis was performed using STATA version 14 (StataCorp, College Station, TX, USA).
RESULTS
Baseline characteristics by registry diagnosis
A total of 417 AIPFR participants have undergone central registry MDD. There was no significant difference in the baseline characteristics of all participants who had completed MDD (n = 417) compared to those who are awaiting MDD (n = 230; Table S2 Baseline characteristics, categorized by diagnostic classification, are shown in Table 1 . Participants with 'definite IPF' were more commonly male. Those with 'possible/probable IPF' were older and had milder disease characterized by higher FVC and diffusing capacity of the lung for carbon monoxide (DL CO ) % predicted. However, those participants who did not meet diagnostic criteria for IPF had more severe physiological impairment, with lower FVC and DL CO % predicted.
Classification of IPF using current ATS/ERS guidelines
The majority of the 417 participants undergoing diagnostic review at registry MDD had their IPF diagnosis confirmed ('guideline adherent IPF'; n = 322; 77%) with most of them having definite IPF (n = 202, 48%). There were few participants diagnosed with 'probable IPF' (n = 28, 7%) with a larger number diagnosed with 'possible IPF' (n = 92, 22%). Ninety-five participants (23%) did not meet the diagnostic criteria for IPF and so were classified as 'inconsistent with IPF' (Fig. 1) . None of the participants with histopathology had features inconsistent with UIP.
The main reason participants were considered to be inconsistent with IPF according to diagnostic guidelines was on the basis of radiological features inconsistent with UIP, which were present in 69 of 95 (73%) participants. These features included ground-glass changes, upper lobe predominance and mosaic attenuation present in 59%, 32% and 20% of the HRCT, respectively, with some HRCT having multiple inconsistent features ( Table 2 ). The other major basis for inconsistent categorization was the presence of an underlying connective tissue disease and self-reported questionnaires in 26 of the 95 (27%) participants (rheumatoid arthritis n = 22; scleroderma n = 1; other n = 3). The majority of these participants had definite UIP on HRCT (n = 16) with only one participant having an HRCT pattern inconsistent with UIP. Three participants did not have a diagnostic HRCT and IPF diagnosis was made based on histopathology and clinical features.
Natural history of patients in the AIPFR
Annual change in FVC% predicted
There was no significant difference between the annual change in FVC% predicted between participants with guideline adherent IPF and those with inconsistent with IPF (4.2%/year, 95% CI: 3.2-5.2% and 4.8%/year, 95% CI: 2.6-6.9%, respectively; P = 0.65). In participants with definite IPF, the decline in FVC% predicted was 4.9%/year (95% CI: 3.8-6.1%), while in those with possible/probable IPF the decline was 3.2%/ year (95% CI: 1.5-4.8%). The apparent trend towards faster decline in FVC% predicted in definite IPF was not statistically significant (P = 0.08).
Overall survival
Participants with guideline adherent IPF and those with an inconsistent with IPF diagnosis had identical outcomes on univariate Cox analysis for overall survival (hazard ratio (HR): 0.91, 95% CI: 0.61-1.38; P = 0.67) (Fig. 2A) . The presence of honeycombing on HRCT was associated with increased mortality (HR: 1.90, 95% CI: 1.29-2.78; P < 0.001) (Fig. 2B ) and this translated to higher mortality within the definite IPF subgroup (HR: 1.79, 95% CI: 1.13-2.84; P = 0.013). Older age, lower BMI and lower baseline lung function were all also associated with increased mortality (Table 3) .
These above-mentioned results were unchanged following multivariate Cox regression analysis, including age, gender, smoking status and baseline FVC% predicted (Table  S3 , Supplementary Information).
Concordance of diagnostic categories and specific UIP features Radiology concordance
The overall concordance for the diagnostic categories for UIP on HRCT was moderate (κ w = 0.51, 95% CI: 0.44-0.59 and κ w = 0.43, 95% CI: 0.35-0.52). There was (Table 4) . The concordance for the presence of 'any inconsistent feature' was also only moderate to fair. The concordance for the presence of ground-glass change, a commonly cited inconsistent feature in our cohort, was fair at best (κ w = 0.37, 95% CI: 0.24-0.51 and κ w = 0.27, 95% CI: 0.14-0.41), as was the presence of mosaic attenuation (κ w = 0.34, 95% CI: 0.08-0.62 and κ w = 0.35, 95% CI: 0.16-0.55). Concordance for other specific inconsistent features was fair to poor (Table 5) .
Histopathology concordance
The analysis of inter-observer agreement in histopathology showed moderate overall concordance. Concordance for the presence of specific features was, however, poor with concordance of only κ w = 0.06 (95%CI: −0.05 to 0.18) for fibroblastic foci, a key histopathological feature of UIP (Table 5 ). This very low kappa, however, reflects the high frequency with which fibroblast foci was reported as present and thus high expected concordance (95% by two reviewers and 71% by the other reviewer). Of the inconsistent features, concordance regarding the presence of granulomas was highest but concordance regarding other inconsistent features was fair to poor. 
Clinical concordance
The overall concordance of registry MDD diagnosis by clinicians after radiological and histopathological review was high (κ w = 0.86, 95% CI: 0.82-0.89). This was strongly influenced by the consensus radiological diagnosis with interdisciplinary agreement of κ w = 0.78 (95% CI: 0.73-0.83) between consensus radiological and clinical diagnosis. This is unsurprising as most patients did not have histopathology for review.
DISCUSSION
In our national IPF cohort, 23% of patients diagnosed with IPF in clinical practice did not meet IPF diagnostic criteria, mostly due to the presence of inconsistent radiological features in the absence of a surgical lung biopsy. However, these patients demonstrated no difference in disease progression or overall survival when compared with the guideline adherent group, suggesting that they may indeed have IPF despite not fulfilling the diagnostic criteria. Concordance for the UIP pattern and specific features on radiology and histopathology was modest at best, with honeycombing having the best overall concordance. These findings highlight the presence of a cohort of patients considered to have IPF by their treating respiratory physician, who behave like IPF, but do not meet criteria for IPF diagnosis.
The AIPFR includes IPF patients from diverse geographical locations and clinical settings in Australia, including tertiary ILD centres as well as regional pulmonology practices. Given the diversity of referring respiratory physicians, we applied the ATS/ERS/JRS/ ALAT guidelines through our registry MDD to assess the rate of adherence to diagnostic guidelines. While our findings were largely based on the radiology as only 15% of patients had lung biopsy, we found that overall adherence to guidelines was high with 77% of patients meeting guideline criteria for IPF (definite, probable or possible IPF). Twenty-three percent were inconsistent with IPF, largely due to radiology features inconsistent with UIP in patients who did not undergo biopsy. While it is possible that these patients did not have IPF, it is also possible that clinicians may be using other factors including age, gender and disease behaviour in their clinical judgement when making a clinical IPF diagnosis. 11, 12, 16 Our findings support growing evidence that in patients where there is a high clinical suspicion of IPF, an atypical scan does not exclude IPF. In the study by Brownell et al., a possible UIP pattern on HRCT had high specificity for UIP on biopsy, but an inconsistent with UIP pattern had poor positive predictive value. This study was performed in a general ILD cohort where only about 25% of patients had IPF. 16 In populations where IPF is highly prevalent like ours, an HRCT inconsistent with UIP has been associated with rates of UIP on histopathology as high as 94.7% 17 with other studies showing rates of 62% 18 and 82%. 19 As with our population where overall survival was unaffected by inconsistent UIP features, in a study of 98 patients with histopathological UIP by Sumikawa et al., there was also no difference in survival based on the HRCT UIP classification (definite, possible or inconsistent). Instead, specific radiological features including traction bronchiectasis and fibrosis score were the most significant predictors of survival. 20 Our study demonstrated no difference in the annual FVC decline between definite IPF and possible/probable IPF groups. Interestingly, in a post hoc analysis of pooled data from the INPULSIS trials by Raghu et al., 21 there was no difference in the adjusted annual rate of decline in FVC in patients with definite UIP compared with possible UIP with traction bronchiectasis, although survival data were limited due to the shorter duration of this study. Raghu et al. also showed that there was no difference in the efficacy of nintedanib between possible and definite UIP groups, suggesting broad efficacy of nintedanib in IPF. 21 While it is not possible to extrapolate these results to our registry participants, it does raise the question as to whether patients who are considered to have IPF by their treating physicians, but who do not fulfil the IPF diagnostic criteria would benefit from receiving anti-fibrotic therapy? In some countries, including Australia, anti-fibrotic therapy is restricted to patients with a confirmed diagnosis of IPF at ILD multidisciplinary meeting. We suggest that this group of patients who behave clinically like IPF, but who do not fulfil radiological and/or histological criteria for IPF, may benefit from a trial of anti-fibrotic therapy.
Our study also shows that specific radiological features predict survival, with the presence of honeycombing being associated with poorer prognosis. This has been shown in other studies 22 and has also been demonstrated for other radiological features including the extent of fibrosis and traction bronchiectasis. 20, [23] [24] [25] The increased mortality associated with the definite IPF group compared with possible/probable IPF in our study is likely influenced by the presence of honeycombing, the key defining feature separating these two groups.
In our study, the concordance for honeycombing on radiology was moderate (κ w = 0.54-0.56) and had the highest concordance among UIP features, similar to other concordance studies. 10 Concordance for features inconsistent with UIP was only fair at best: groundglass change (κ w = 0.27-0.37); mosaic attenuation (κ w = 0.34-0.35) and peribronchovascular distribution (κ w = 0.09-0.18). While in an ideal world, these patients would have a surgical lung biopsy to confirm their diagnosis, many patients are unwilling or unable to undergo this procedure as it can be associated with significant morbidity and mortality in this older population with frequent co-morbidities. [26] [27] [28] Thus, it is possible that patients may be excluded from an IPF diagnosis based on features that are inconsistently reported. It is also important to note that even when clinical as well as histopathological data are taken into account, several studies have shown only moderate concordance for IPF diagnosis between physicians 29 as well as between multidisciplinary meetings. 30 Our study has several limitations. First, as this is a real-world registry, variation in the investigations and monitoring undertaken was present, as this was determined by the treating respiratory physician. Every effort was made, however, to ensure that all data regarding the participant were captured; the large number and diversity of participants allowed us to explore the natural history of IPF within these limitations. Of note, the rate of lung biopsy in patients with possible or inconsistent UIP was low. For the purposes of our analysis, these patients were pragmatically given a diagnosis based on radiology and clinical features. Second, it must also be noted that the registry MDD is a virtual MDD where all reviewers assess participants independently and not at the same time and location. However, the final clinical reviewers did have the comprehensive data from the radiology and histopathology reviews available to them.
Finally, while we can demonstrate the natural history, we cannot make any assumptions about the pathobiology or corresponding potential response of different IPF groups to treatment, particularly those with inconsistent with IPF diagnosis, as this group has been largely excluded from clinical trials. 4, 5, 31, 32 Finally, 26 of the 95 (27%) participants were considered to have inconsistent with IPF diagnosis due to the presence of a concomitant connective tissue disease (CTD). Given the potential lack of reliability of patient-reported diagnoses, we performed sensitivity analysis excluding these patients, and there remained no difference for the outcomes demonstrated (Table S4 , Supplementary Information).
In summary, our findings have important implications for the clinical application of IPF diagnostic guidelines. The guidelines have been instrumental in advancing our knowledge of IPF and providing homogeneous cohorts for clinical trials. However, in clinical practice, we demonstrate a cohort of patients who are sufficiently similar in their presentation to IPF, that their treating clinicians assign them an IPF diagnosis although they do not, strictly speaking, fulfil IPF diagnostic criteria. While their radiology is inconsistent with IPF and lung biopsy has not been performed, we show that these participants demonstrate identical longitudinal disease behaviour to participants with radiology and/or pathology consistent with IPF. Further study of this cohort is crucial, as the decision to assign an IPF diagnosis to a patient has major implications with regard to prognosis and indeed management. Figure S1 . The AIPFR multidisciplinary panel. Figure S2 . Kaplan-Meier plot of mortality for the AIPFR cohort. Table S1 . (A) Radiological classification of usual interstitial pneumonia (UIP). (B) Histopathological classification of UIP. (C) Diagnostic criteria for idiopathic pulmonary fibrosis. Table S2 . Baseline characteristics of patients who have undergone registry MDD. Table S3 . Multivariable analysis for mortality. Table S4 . Multivariate analysis excluding patients with a connective tissue disease diagnosis.
